Особенности структурно-функционального состояния миокарда у больных с хронической почечной недостаточностью
Диссертация
У большинства больных при развитии ХПН наблюдается поражение миокарда, которое, в свою очередь, значительно влияет на тяжесть состояния и прогноз жизни у этих больных. Миокардиальные заболевания являются наиболее частой причиной смерти в терминальной стадии ХПН (14 -50% от всех причин смерти). При этом только у небольшого числа лиц развивается терминальная стадия ХПН, требующая назначения… Читать ещё >
Список литературы
- Абрикосов А.И. Частная патологическая анатомия (выпуск II). Ленинград.: Медгиз, 1947. 574 с.
- Алмазов В.А., Шляхто Е. В. Артериальная гипертензия и почки. СПб.: Издательство СПбГМУ, 1999.-295 с.
- Багрий А.Э. Сердечно-сосудистые нарушения при хронической почечной недостаточности //Тер. архив. 1998. — № 11. — С. 80−83.
- Белоусов Ю.Б., Леонова М. В. Антагонисты кальция пролонгированного действия и сердечно-сосудистые заболевания: Новые данные доказательной медицины // Кардиология. — 2001. № 4. — С. 87−93.
- Боровиков В. STATISTICA: искусство анализа данных на компьютере. Для профессионалов. СПб.: Питер, 2001. — 656 с.
- Бохуа М.Р., Даушвили Э. Р., Маглакелидзе Т. А. Изменение систолической и диастолической функций левого желудочка при лечении артериальной гипертензии НОРМОДИПИНомк// Гедеон Рихтер в СНГ. 2002. — № 1. -С. 19−20.
- Волгина Г. В., Перепеченых Ю. В., Бикбов Б. Т., Ушакова А. И., Китаева Ю. В., Грябина Н. А., Томилина Н. А. Факторы риска кардиоваскулярных заболеваний у больных с хронической почечной недостаточностью // Нефрология и диализ -2001. -т. 3. -№ 2. — С. 15−21.
- Гельман В.Я. Медицинская информатика: практикум (2-е изд.). — СПб.: Питер, 2002.-480 с.
- Дядык А.И., Багрий А. Э., Лебедь И. А. Гипертрофия левого желудочка сердца у больных с хронической почечной недостаточностью // Кардиология. 1997. — № 2. — С. 76−82.
- Ермаков Ю.А., Каюков И. Г., Ковальский Г. Б., Черемисина И. Л. Частота выявления хронической почечной недостаточности в Санкт-Петербурге по данным патологоанатомических исследований за 1993−1997 гг. // Нефрология. 2000. — т. 4 — № 3. — С. 67−71.
- Ермоленко В.М. Эритропоэтин и гипертония у больных с преддиализной хронической почечной недостаточностью // Нефрология. — 2000. — т. 4. -№ 1. С. 122−123.
- Ермоленко В.М. Хронический гемодиализ. М.: Медицина. — 1982. — 278с.
- Есаян A.M., Найденова Н. В., Румянцев А. Ш., Гудкова А. Я., Семернин Е. М., Смирнова Е. В. Нарушение циркадных ритмов при почечной недостаточности: функционально-гемодинамические параллели // Нефрология. 2003. — т. 7. — № 1, приложение 1. — С. 85−86.
- Зотов Д.Д., Гротова А. В. Современные методы функциональной диагностики в кардиологии / Под ред. Ю. Р. Ковалева. СПб.: Фолиант. — 118 с.
- Караулова Ю.JI. Клинико-генетические детерминанты чувствительности / устойчивости гипертрофии левого желудочка к антигипертензивной терапии. Автореф. дис. канд. мед. наук. М., 2001. -21 с.
- Карпов Ю.А. Применение антагонистов кальция у больных артериальной гипертензией и ишемической болезнью сердца: Современное состояние вопроса // Кардиология. 2000. — № 10. — С. 52−55.
- Кобалава Ж.Д., Котовская Ю. В. Мониторирование артериального давления: методические аспекты и клиническое значение. М., 1999. -234с.
- Коношкова P.JI. Ишемические изменения миокарда у больных с хронической почечной недостаточности, получающих терапию гемодиализом // Нефрология. 2000. — т. 4. — № 3. — С. 18−26.
- Левина Л.И. Сердце при эндокринных заболеваниях. Ленинград: Медгиз, 1989.-263 с.
- Лисовский В.А., Евсеев С. П., Голофеевский В. Ю., Митоненко.А. Н. Комплексная профилактика заболеваний и реабилитация больных и инвалидов: Учебн. пособие./Под редакцией проф. Евсеева. М.:Советский спорт.-2001.- 320с.
- Лукичев Б.Г. Гемодиализный больной проблема амбулаторного лечения // Новые Санкт-Петербургские врачебные ведомости. — 2000. — № 2. — С. 4548.
- Михеева Ю.С. Нарушения ритма и гипертрофия левого желудочка у больных с хронической почечной недостаточностью, получающих лечение гемодиализом // Нефрология. 2000. — т. 4. — № 3. — С. 27−40.
- Николаев А.Ю. Особенности диализной гипертонии // Нефрология. 2000.- т.4. № 1.-С. 96−108.
- Николаев А.Ю., Милованов Ю. С. Лечение почечной недостаточности: Руководство для врачей. М.: ООО «Медицинское информационное агенство», 1999. — 363 с.
- Орлов А.В. Состояние миокарда при хронической почечной недостаточности. Автореф. дис. канд. мед. наук Ленинград. — 1986. — 17 с.
- Преображенский Д.В., Сидоренко Б. А., Шабаева Е. Н. Амлодипин-антагонист кальция третьего поколения // Кардиология. — 1998. № 2. — С. 66−73.
- Рекомендации по профилактике, диагностике и лечению артериальной гипертензии // Гедеон Рихтер в СНГ. 2002. — № 1. — С. 8−10.
- Рекомендации по профилактике, диагностике и лечению артериальной гипертензии. Рекомендации разработаны экспертами Всероссийского научного общества кардиологов. // Артериальная гипертензия. — 2001 — т. 7.-№ 1.-С. 3−16.
- Рябов С.И. Нефрология: руководство для врачей. СПб.: СпецЛит. — 2000.- 672 с.
- Смирнов А.В. Уремическая дислипопротеидемия // Нефрология. — 1998. — т.2, № 1. С.14−21.
- Смирнов А.В., Добронравов В. А., Румянцев А. Ш., Мнускина М. М. Факторы риска ИБС у больных, получающих лечение гемодиализом // Нефрология. 2003. — т. 7. — № 1, приложение 1. — С. 7−13.
- Стецюк Е.А. Основы гемодиализа. М.: ГЭОТАР-МЕД, 2001. — 320с.
- Чазова И.Е. Современные подходы к лечению легочного сердца // Русский медицинский журнал. 2000. — № 2. — С. 83−86.
- Чупрасов В.Б. Программный гемодиализ. СПб.: Фолиант. — 2001. — 252 с.
- Шевченко Ю.Л., Бобров Л. Л. Обрезан А.Г. Диастолическая функция левого желудочка. М.: ГЕОТАР-МЕД, 2002. — 240 с.
- Шиллер Н., Осипов М. А. Клиническая эхокардиография. М.: 1993. -347с.
- Шило Ю.В., Денисов А. Ю., Гендлин Г. Е., Перекокин Ю. Н., Сторожаков Г. Е. Кардио-васкулярные аспекты нарушений фосфорно-кальциевого обмена у больных на программном гемодиализе // Нефрология. 2003. — т. 7, прил.1.-С. 368−369.
- Шишкин А.Н. Современные проблемы уремической кардиопатии // Нефрология. 2003. — т. 7, прил. 1. — С. 14−20.
- Шляхто Е.В., Конради А. О., Захаров Д. В., Рудоманов О. Г. Структурно -функциональные изменения миокарда у больных гипертонической болезнью // Кардиология. 1999. — № 2. — С. 49−55.
- Шутов A.M., Кондратьева Н. И., Куликова Е. С. и др. Ремоделирование сердца у больных с хронической почечной недостаточностью в стадии, не требующей диализа // Тер. Арх. 2000. — № 6. — С. 46−49.
- Юнкеров В.И., Григорьев С. Г. Математико-статистическая обработка данных медицинских исследований. — СПб.: ВмедА, 2002. 266 с.
- Abergel R., Tase М., Bohlander J. Which definition for echocardiography left ventricular hypertrophy? // Am. J. Cardiol. 1995. — Vol. 75. — P. 489−503.
- Abernethy D.R. The pharmacokinetic profile of amlodipine // Am. Heart J. — 1989.-Vol. 189.-P. 1100−1103.
- Agabiti-Rosei E., Muiesan M.L., Rozzoni D. Cardiovascular structural changes and calcium antagonist therapy in pationts with hypertension // J. Cardiovasc. Pharmacol. 1994. — Vol. 24 (Suppl.A). — P. S37-S43.
- Agarwal R. Supervised atenolol therapy in the management of hemodialysis hypertension // Kidney Int. 1999. — Vol. 55. — № 4. — P. 1528−1535.
- Ahaneku J.E., Taylor G.O., Agbedana E.O. Effects of amlodipine on plasma lipid and lipoprotein levels in hypertensive patients // J. Intern. Med. — 1992. — Vol. 232.-P. 489−493.
- Akmal S.U., Massry S.G., Goldstein D.A. Role of parathyroid hormone in the glucose intolerance of chronic renal failure // J. Clin. Invest. 1985. — Vol. 75. -P. 1037−1044.
- Alderman M.H. Serum uric acid as a cardiovascular risk factor for heart disease // Current Hypertension Reports. 2001. — Vol. 3. — P. 184−189.
- Alpert M.A., Wizemann V. Noninvasive assessment of left ventricular structure and function in patients with end stage renal disease // Contrib. Nephrol. — 1994.-Vol. 106.-P. 13−25.
- Amann K., Gross Marie-Luise, London G. M. Hyperphosphataemia—a silent killer of patients with renal failure? // Transplant. 1999. — Vol. 14. — P. 20 852 087.
- Amann K., Rychlik I., Miltenberger-Milteny G., Ritz E. Left ventricular hypertrophy in renal failure // Kidney Int. 1998. — Vol. 54, Suppl. 68. — P. S78-S85.
- Amann K., Ritz E. Cardiac disease in chronic uremia: pathophysiology // Adv. Renal Replace Ther. 1997. — Vol. 4. — P. 212−224.
- Amann K., Tornig J., Buzello M., Kuhlmann A., Gross M.L., Adamczak M., Buzello M., Ritz E. Effect of antioxidant therapy with dl-alpha-tocopherol on cardiovascular structure in experimental renal failure // Kidney Int. 2002. -Vol. 62.-№ 3.-P. 877−884.
- Appleby C., Foley R.N. Hypertension in end-stage renal disease // Minerva Urol. Nefrol. 2002. — Vol. 54. — № 1. — P. 37−43.
- Aronoiv W.S., Schwartz K.S., Koenisberg M. Correlation of atrial fibrillation with presence of mitral annular calcium in 604 person older than 60 years // Am. J. Cardiol. 1987. — Vol. 59. — P. 1213−1214.
- Bagnati M., Perugini C., Cau C. When and why a water soluble antioxidant becomes prooxidant during copperinduced lowdensity lipoprotein oxidation: a study using uric acid // Biochem. J. 1999. — Vol. 340. — P. 143 — 152.
- Baigent C., Burbury K., Wheeler D. Premature cardiovascular disease in chronic renal failure //Lancet. 2000. — Vol.356. — № 8. — P. 147−152.
- Bakris G.L., Shaikh M. Calcium channel blockers and progression of renal disease: clinical studies put into perspective // J. Nephrology. 1996. — Vol.9. -№ 6.-P. 263−265.
- Barenbrock M., Spieker G., Laske V. Studies of the vessel wall properties in hemodialysis patients // Kidney Int. 1994. — Vol. 45. — P. 1397−1400.
- Barrett В .J., Parfrey P. S., Morgan J. Prediction of early death in end stage renal disease patients receiving dialysis // Am. J. Kidney Dis. — 1997. Vol. 29. — P.214−222.
- Berweek S., Hennig L., Sternberg C. Cardiac mortality prevention in uremic patients. Therapeutic strategies with particular attention to complete correction of renal anemia // Clin. Nephrol. 2000. — Vol. 53, Suppl. 1. — P. S80-S85.
- Blacher J., Guerin A.P., Pannier В., Marcbais S.J., Safar M.E., London G.M. Impact of aortic stiffness on survival in end-stage renal disease // Circulation. -1999. Vol. 99. — P. 2434−2439.
- Bologda R.M., Levine D.M., Parket T.S. Interleukine 6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. // Am. J. Kidney Dis. 1998. — Vol. 32. — P. 107−114.
- Bommer J. Medical complications of the long-term dialysis patients / Eds. Cameron S., Davison A.M., Grunfeld J.P., Kerr D., Ritz E. Oxford University, 1992.-P. 1436−1458.
- Braun E.M., Pollak M. // Am. J. Kid. Dis. 1996. — Vol. 27. — P. 394−401.
- Brown J.H., Hunt L.P., Vites N.P. Comparative mortality from cardiovascular disease in patients with chronic renal failure // Nephrol. Dial. Transplant. -1994. Vol. 9. -№ 8. — P. 1136−1142.
- Bullock R.E., Haissein A.A., Simpson I., Ward M.K. Cardiac abnormalities and exercise tolerance in patients receiving renal replecement therapy // BMJ. -1984. Vol. 28. — P.1479−1484.
- Buoncristiani U., Fagugli R., Ciao G. Left ventricular hypertrophy in daily dialysis // Miner. Electrolyt. Metab. 1999. — Vol. 25. — P. 90−94.
- CAMELOT: Comparison of amlodipin versus enalapril to limit occurrences of thrombosis. Data on file. -N.Y.: Pfizer Inc, 1999. 386 c.
- Canau A., Devereux R.B., Roman M.J. et al. Patterns of ventricular hypertrophy and geometric remodeling in essential hypertension // J. Am. Coll. Cardiol. -1992.-Vol. 19.-P. 1550−1558.
- Cannella G. Left ventricular hypertrophy in the dialysed patient. What can be done about it? // Nephrol. Dial. Transplant. 1996. — Vol. 11. — Vol. 3. — P. 418−420.
- Cannella G., Paoletti E., Ravera G. Inadequate diagnosis and therapy of arterial hypertension as causes of left ventricular hypertrophy in uremic dialysis patients // Kidney Int. 2000. — Vol. 58. — № 1. — P. 260−268.
- Carlini R., Obialo C., Rothstein S. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in haemodialysis patients // Am. J. Hypertens. 1993. — № 6. — P. 103.
- Cerasola G., Mule G., Vecchy M. Sympathetic activity and blood pressure pattern in patients with ADPKD // J. Hypertens. 1998. — Vol. 16. — P. 184.
- Cetinkaya F., Baysal К., Kocak H., Gurses N. The incidence and significance of increased backscatter in myocardial ultrasonography of patients on hemodialysis // Nephron. 1996. — Vol. 73. — P. 191−194.
- Chakko S., Girgis I., Contreras G. Effects of hemodialysis in left ventricular diastolic filling // Am. J. Cardiol. 1997. — Vol. 79. — P. 106−108.
- Chen Y.F., Jang R.H., Meng.Q.C. Sodium-proton (NaVH4-) exchange inhibition increases blood pressure in spontaneously hypertensive rat // Am. J. Med. Sci. — 1994.-Vol. 308.-P. 145−151.
- Collins A., Va J., Umen A. Urea index and other predictors of hemodialysis patient survival // Am. J. Kidney Dis. 1994. — Vol. 23. — P. 272−282.
- Conlon P.J., Kovalik E., Schumm D., Minda S., Schwab S.J. Normalization of hematocrit in hemodialysis patients does not affect silent ischemia // Ren. Fail. 2000. — Vol. 22. — № 2. — P. 205−211.
- Covic A., Goldsmith D.J.A., Clayton P. Long-term hemodialysis vs. renal transplantation: comparative influence on cardiac structure and function // Nephrol. Dial. Transplant. 1994. — Vol. 9. — P. 980−981.
- Covic A., Goldsmith D.J.A., Georgescu D. Echocardiography findings in long-term, long-hour hemodialysis patients // Clin. Nephrol. 1996. — Vol.45. — № 2. -P. 104−110.
- Csiky В., Kovacs Т., Nagy J. Ambulatory blood pressure monitoring in IgA nephropathy // J. Hypertens. 1998. — Vol. 16. — P.184.
- Dahan M., Siohan P., Viron B. Relationship between left ventricular hypertrophy, myocardial contractility, and load conditions in hemodialysis patients: an echocardiographic study // Am. J. Kidney Dis. 1997. — Vol. 30. -№ 6.-P. 780−786.
- Dahlof В., Pennert K., Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies // Am. J. Hypertens. 1992. — Vol. 5. — P. 95−100.
- Devereux R.B., Alonso D.R., Lutas E.M., Gotlieb G.J. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings // Am. J. Kidney Dis. 1991. — Vol. 18, Suppl. 2. -P.121−127.
- Devereux R.B., Koren M.J., Simone G. Applicaicion to hypertensive heart disease // Eur. Heart J. 1993. — Vol. 14, Suppl D. — P.8−15.
- Dominiczak A.F., Lyall F., Morton J.J. Blood pressure, left ventricular mass and intracellular calcium in primary hyperparathyroidism // Clin. Sci. -1990. -Vol. 78.-P. 127−132.
- Douchet M.P., Couppie P., Chntrel F. Diastolic dysfunction in chronic renal failure patients under hemodialysis // Annalesde Cardiologie et d. angeiologie. -1996. Vol. 45. — № 10. — P. 589−592.
- Drau V.J. The role of mechanical and humoral factors in growth regulation of vascular smooth muscle and cardiac myocytes // Curr. Opin. Nephrol. Hypertens. 1993. — Vol. 2. — P. 27−32.
- Duprez D., Bauwens F., De Buyzere M. Relationship between parathyroid hormone and left ventricular mass in moderate essential hypertention // J. Hypertens.-1991.-Vol. 9, Suppl. 6.-P. 116−117.
- Dyadyk A.I., Bagriy A.E., Yarovaya N.F. Left ventricular hypertrophy in chronic uremia // Dial.& Transplant.- 2000.- Vol.29. № 6. — P. 312−318.
- Fearnandez J.N., Carbonell M.E., Mazzuchi N., Petruccelli D. Simultaneous analysis of morbidity and mortality factors in chronic hemodialysis patients // Kidney Int. 1992. — Vol. 41. — P. 1029−1034.
- Feigenbaum H. Echocardiography. 4th ed. Philadeiphia: Lea & Febiger, 1986.-P. 582.
- Fernandez-Reye M.J., Auxiladora Bajo M., Robles P. Mitral annular calcification in CAPD patients with a low degree of HPT. An analysis of other possible risk factors. // NDT 1995. — Vol. 10. — P. 2090−2095.
- Final Report of bioequivalence study of Amlodipin 10 mg (Gedeon Richter Ltd) and Istin 10 mg (Pfizer) tablets in healthy volunteers. Final version. -Budapest, 1998.-28 p.
- Flather M.D., Yusuf S., Kober L. et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients // Lancet. 2000. — Vol. 355. — P. 1575−1581.
- Fliser D., Franek E., Fode P. Subacute infusion of physiologic doses of parathyroid hormone raises blood pressure in humans // Nephrol. Dial. Transplant. 1997. — Vol. 12. — P. 933−938.
- Fogari R. Amlodipine and Fosinopril Curb Hypertension, Albuminuria in Hypertensive Diabetics // Am. J. Hypertens. 2002. — Vol. 15. — P. 1042−1049.
- Foley R.N., Parfrey P. S. Cardiac function and cardiac disease in renal failure. Primer on kidney disease. Ed. A. Greenberg, Academic Press. 1998. — P. 455 459.
- Foley R.N., Parfrey P. S., Harnett J.D. Clinical and echocardiographic disease in end-stage renal disease: prevalence, associations and prognosis // Kidney Int. 1995.-Vol. 47.-P. 186−192.
- Foley R.N., Parfrey P. S., Harnett J.D. Impact of hypertension on cardiomypathy, morbidity and mortelity in end-stage renal disease // Kidney Intern. 1996. — Vol.49. — P. 1379−1385.
- Foley R.N., Parfrey P. S., Harnett J.D. The prognostic importance of left ventricular geometry in uremic cardiomyopathy // J. Am. Soc. Nephrol. 1995. -Vol. 5.-P. 2024−2031.
- Foley R.N., Parfrey P. S., Hefferton D. Advance prediction of death in patients starting maintenance dialysis // Am. J. Kidney Dis. 1994. — Vol. 23. — P. 836 845.
- Foley R.N., Parfrey P. S., Kent G.M. Long-term evolution of cardiomyopathy in dialysis patients // Kidney Int. 1998. — Vol. 54. — Vol. 5. — P. 1720−1725.
- Foley R.N., Parfrey P. S., Morgan J. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy // Kidney Int. 2000. -Vol. 58.-№ 3.- P. 1325−1335.
- Fratolla A., Parati G., Cuspidi C. Prognostic value of 24-hour pressure variability // J. Hypertens. 1993. — Vol. 11. — P. 1133−1137.
- Frohlich E.D. The heart in hypertension // Clin. Nephrol. 1991. — Vol. 36. — P. 160−165.
- Fujimoto S., Hisanaga S., Yamatomo Y., Tanaka K., Hayashi Т., Sumiyoshi A. Tertiary hyperparathyroidism associated with metastatic cardiac calcification in a haemodialyzed patient // Int. Urol. Nephrol. 1991. — Vol. 23. — P. 285−92.
- Galderisi M., Benjamin E., Evans J. Impact of heart rate and PR-interval on Doppler indexes of left ventricular diastolic filling in an elderly cohort (the Framingham heart study)//Am. J. Cardiol. 1993.-Vol. 72.-P. 1183−1187.
- Gault M.H., Barret B.J. Dialysis therapy in patients with cardiac disease // Cardiac disfunction in chronic uremia / Ed. P. S. Parfrey, J.D. Harriett. Boston. -1992.-P. 273−275.
- Gentil M.A., Carriazo A., Pavon M.I. Comparison of survial in continuons ambulatory peritoneal dialysis and hospital hemodialysis. A multicentric study //Nephrol. Dial. Transplant. 1991. — Vol. 6. -P. 444−451.
- Goya Wannamethee S. Serum Uric Acid Is Not an Independent Risk Factor for Coronary Heart Disease // Current Hypertension Reports. 2001. — Vol. 3. — P.190- 196.
- Greaves S.C., Gamble G.D., Collins J.E. Determinants of left ventricular hypertrophy and systolic dysfunction in chronic renal failure // Am. J. Kidney Dis. 1994. — Vol. 24, Suppl. 5. — P. 768−776.
- Ha S.K., Park H.S., Kim S.U. Prevalence and patterns of left ventricular hypertrophy in patients with predialysis chronic renal failure // J. Korean Med. Sci. 1998. — Vol. 13, Suppl. 5. — P. 488−494.
- Hakim J.G., George A., Siziyo S. Echocardiographic assessment of left ventricular hypertrophy diastolic dysfunction and pericardial disease in patients on maintenance hemodialysis // East. Afr. Med. J. 1996. — Vol. 73. — № 8. — P. 50−58.
- Hara S., Ubara Y., Arisono K. Relation between parathyroid hormone and cardiac function in long-term hemodialysis patients // Miner. Electrolyte Metab. 1995.-Vol. 21.-P. 72−76.
- Haria M., Wagstaff A.T. Amlodipine // Drugs. 1995. — Vol. 50. — № 3. — P. 567−584, 171.
- Harnett J.D., Foley R.N., Kent G.M. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors // Kidney Intern. -1995.- Vol.47. -P. 884−890.
- Harnett J.D., Kent G.M., Barre P.E. Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients // J. Am. Soc. Nephrol. 1994. — Vol. 4. — P. 1486−1490.
- Harnett J.D., Murphy В., Collingwood P., Parfrey P. S. The reability and validity of echocardiographic measurement of left ventricular mass in hemodialysis patients // Nephron 1993. — Vol. 65. — P.212−214.
- Harnett J.D., Parfrey P. S. Left ventricular dysfunction in dialysis patients. Henrich WL (ed): Principles and practice of dialysis. Baltimore, MD Williams, Willkins. — 1995. — P. 170−180.
- Harris D.C.H., Hammond W.S., Burke T.J., Schrier R.W. Verapamil protects against progression of experimental chronic renal failure // Kidney Int. 1987. -Vol. 31.-P. 41−46.
- Heart Outcomes Prevention Evaluation (HOPE) study investigators. Effects of angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients // New Engl. J. Med. 2000. — Vol. 342. — P. 145−153.
- Held P.J., Levin N.W., Pauly M.V., Diamond L.H. Mortality and duration of hemodialysis treatment // JAMA. 1991. — Vol. 265. — P. 871−875.
- Herzog C.A., Ma J.Z., Collins A J. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis // N. Engl. Med. -1998. Vol. 339. — P. 799−805.
- Hsu C.H. Are we mismanaging calcium and phosphate metabolism in renal failure // Am. J. Kidney Dis. 1997. — Vol. 29. — P. 641−649.
- Huchins G.M. Cardiac pathology in chronic renal failure // Cardiac dysfunction in chronic uremia / Ed. P. S. Parfrey, J.D. Harnett. Boston. 1992. — P. 86−104.
- Imanishi Y., Kishiro M., Miyazaki O., Toyokawa Т., Kuroki K., Haji H., Ishikawa T. Multiple metastatic calcifications detected by bone scintigraphy and demonstrated by CT // Clin. Nucl. Med. 1992. — Vol. 17. — P. 114−118.
- Johnson R.J., Schreiner G.F. Hypothesis: The role of acquired tubulointerstitial disease in the pathogenesis of salt-dependent hypertension // Kidney Intern. -1997.-Vol. 52.-P. 1169−1179.
- Kanegae К., Hiroshige К., Suda Т. Pharmacokinetics ofbisoprolol and its effect on dialysis refractory hypertension // Int. J. Artif. Organs. 1999. — Vol. 22. -№ 12.-P. 798−804.
- Kannel W.B., Cobb J. Left ventricular hypertrophy and mortality- results from the Framingham study // Cardiology. 1992. — Vol. 81. — P. 291−298.
- Kassiske B.L., Ma J.K., Roberto S.N. Effects of antihypertensive therapy on serum lipids // Ann. Intern. Med. 1995. — Vol. 122. — № 2. — P. 133−141.
- Kawagishi Т., Nishizawa Y., Konishi Т., Kawasaki K., Emoto M., Shoji T. High-resolution B-mode ultrasonography in evaluation of atherosclerosis in uremia // Kidney fat. 1995. — Vol. 48. — P. 820−826.
- Kestenbaum В., Gillen D.L., Sherrard D.J., Seliger S., Ball A., Stehman-Breen K. Calcium channel blocker use and mortality among patients with end-stage renal disease // Kidney International- 2002. Vol. 61, Issue 6. — P. 2157 (Abstract).
- Kikert D., Mitch W. The Heart. Ed. R.C.Schlant.- New Jork, 1994. P. 19 611 970.
- Klahr S., Levey A.C., Beck G.I. The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. Modification of diet in renal disease study group // New Engl. J. Med. 1994. — Vol. 330. -P. 877−884.
- Kunz K., Petitjean P., Lisri M. Cardiovascular morbidity and endothelial dysfunction in chronic heamodialysis patients: is homocysteine the missing link? // Nephrol. Dial. Transplant. 1999.-Vol. 14.-P. 1934−1942.
- Kurz P., Monier-Faugere M.C., Bognar B. Abnormal calcium homeostasis in patients with adynamic bone disease // Kidney Int. 1994. — Vol. 46. — P. 855 861.
- Laragh G. Cardiac pathophysiology and its heterogeneity in patients with established hypertensive disease // Am. J. Med. 1988. — Vol. 84. — P. 3−11.
- Laragh J.H. The renin system and four lines of hypertension research. Lewis K. Dahl. Memorial Lecture // Hypertens. 1992. — Vol. 20. — P. 267−279.
- Levey A.S., Beto J.A., Coronado B.E. Controling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? // Am. J. Kidney Dis. 1998. — Vol. 32. -P.853−906.
- Levey A.S., Eknoyan G. Cardiovascular disease in chronic renal disease// Nephrol. Dial. Transplant. 1999. — Vol. 14. — P. 828−833.
- Levin A., Singer J., Thompson C.R., Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention // Am. J. Kidney Dis. 1996. — Vol. 27. — P. 347−354.
- Levin A., Thompson C.R., Ethier J. Left ventricular mass increase in early renal disease: Impact of decline in hemoglobin // Am. J. Kidney Dis. — 1999, in press.
- De Lima J.J.G., Abensur H., Krieger E.M., Pileggi F. Arterial blood pressure and left ventricular hypertrophy in hemodialysis patients // J. Hypertens. -1996.-Vol. 14.-P. 1019−1024.
- Lindner A., Charra В., Sherrard D., Scribner B.M. Accelerated atherosclerosis in prolonged maintenance hemodialysis // N. Engl. J. Med. 1974. — Vol. 290. -P. 697−702.
- Lindpaintner K., Ganten D. The cardiac rennin-angiotensin system. An appraisal of present experimental and clinical evidence // Circul. Res. 1991. — Vol. 68.-P. 905−921.
- London G.M. Pathophysisology of cardiovascular damage in the early renal population. // N.D.T. 2001. — Vol. 16, Suppl. 2. — P. 3−6.
- London G.M., Drueke T.B. Atherosclerosis and arteriosclerosis in chronic renal failure // Kidney Int. 1997. — Vol. 51. — P. 1678−1695.
- London G.M., Fabiani F. Left ventricular dysfunction in end-stage renal disease: Echocardiographic insights // Cardiac dysfunction in chronic uremia / Ed. P. S. Parfrey, J.D. Harnett. Boston. — 1992. — P. 117−137.
- London G.M., Fabiani F., Marchais S.J. Uremic cardiomyopathy: An inadequate left ventricular hypertrophy // Kidney Int. 1987. — Vol. 31. — P.973−980.
- London G.M., Guerin A.P., Marchais S.J. Cardiac and arterial interactions in end-stage renal disease // Kidney Int. 1996. — Vol. 50. — P. 600−608.
- London G.M., Marchais S.J., Guerin A.P. Cardiac hypertrophy and arterial alteration in ESRD: Hemodinamic factors // Kidney Int. 1993. — Vol. 43, Suppl. 41. — P. 42−49.
- London G, Marshais S, Guerin AP. Blood pressure control in chronic hemodialysis patients. In: Replacement of renal function by dialysis. Fourth edition eds. JF. Winchester, Kluwer Academic publ. 1996. — P. 966−990.
- London G.M., Parfrey P. S. Cardiac disease in chronic uremia: pathogenesis // Advances in Renal Replacement Therapy. — 1997. Vol. 4. — P. 194−211.
- London G.M., Pannier B. Calcification of the aortic valve in the dialyzed patient // J. Am. Soc. Nephrol. 2000. — Vol. 11. — P. 778−783.
- London G.M., Zins В., Pannior B. Vascular changes in hemodialysis patients in response to rHuEPO // Kidney Int. 1989. — Vol. 36. — P. 878−882.
- Lopez-Gomez J.M., Verde E., Perez-Garcia R. Blood pressure, left ventricular hypertrophy and long-term prognosis in hemodialysis patients // Kidney Intern. 1998. — Vol.54, Suppl.68. — P. S-92-S-98.
- Loutzenhiser R.D., Epstein M., Fischetti F., Horton C. Effects of amlodipine on renal haemodinamics // Am. J. Cardiol. 1989. — Vol. 69. — P. 121−181.
- Lowbeer С., Ottisson-Seeberger A. Increased cardiac troponin T and endothelin-I concentrations in dialysis patients may indicate heart disease //Nephrol. Dial. Transplant. 1999. — Vol. 14. — P. 1948−1955.
- Lowrie E.G., Lew N.L. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation ot death rate differences between facilities // Am. J. Kidney Dis. 1990. — Vol. 15. — P. 458 482.
- Macdougall L.C., Lewis N.P., Sounders M.J. Long-term cardiorespiratory effects of amelioration of renal anemia by erythropoietin // Lancet. — 1990. — Vol. 335.-P. 489−493.
- Madore F., Lowrie E.G., Brugnara C. Anemia in hemodialysis patients: variables affecting this outcome predictor // JASN. 1997. — Vol. 8. — P. 19 211 929.
- Mailloux L.U., Haley W.E. Hypertension in the ESRD patients: Pathophysiology, therapy, outcomes, and future directions // Am. J. Kidney Dis. 1998.-Vol. 32.-P. 705−719.
- Maiorca R., Vonesh E.F., Cavalli P.L. A multicenter selection adjusted comparison of patient and technique survivals on CAPD and hemodialysis // Perit. Dial. Int.-1991.-Vol. 11.-P. 118−127.
- Mall G., Huther W., Schneider J. Diffuse intercardiomyocytic fibrosis in uremic patients //Nephrol. Dial. Transplant. 1990. — Vol. 5. — P. 39−44.
- Mall G., Rambausek M., Neumeister A. Myocardial interstitial fibrosis in experimental uremia implication for cardiac compliance // Kidney Int. — 1988. -Vol. 33.-P. 804−811.
- Mallick N.P., Gokal R. Haemodialysis // Lancet. 1999. — Vol.353. — № 27, Issue 9154.-P. 737−742.
- Mann J.F.E. Hypertension and cardiovascular effects-long term safety and potential long-term benefits of r-HuEPO // Nephrol. Dial. Transplant. — 1995. -Vol. 10.-P. 80−84.
- Marchais S.J., Guerin A.P., Pannier B.M., Levy В .J., Safar M.E., London G.M. Wave reflections and cardiac hypertrophy in chronic uremia: influence of body size // Hypertension. 1993. — Vol. 22. — P. 876−83.
- Masahiko Т., Kunitoshi I. Blood pressure variability as an adverse prognostic risk factor in end-stage renal disease. Nephrol. Dial. Transplant // 1999. Vol. 14.-P. 1976−1981.
- McGregor D.O., Buttimore A.L., Nicholls M.G., Lynn K.L. Ambulatory blood pressure monitoring in patients reseiving long, slow home haemodialysis // Nephrol. Dial. Trasplant. 1999. — Vol. 14. — P. 2676−2679.
- Middleton R.J., Parfrey P. S., Foley R.N. Left ventricular hypertrophy in the renal patient // J. Am. Soc. Nephrol. 2001. — Vol. 12. — P. 1079−1084.
- Murdoch D., Heel R.C. Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in cardiovascular disease // Drugs. 1991. — Vol. 47. — P. 478−505.
- National Kidney Foundation Task Force on cardiovascular disease: controlling the epidemic of cardiovascular disease in chronic renal disease // Am. J. Kidney Dis. 1998. — Vol. 32, Suppl. 3. — P. 191−199.
- Nuhbegovic S., Halibasic A., Karamehic J. Morphologic changes in the interventricular septum and the posterior wall of the left ventricular in patients on hemodialysis // Med. Arh. 2000. — Vol. 54. — № 2. — P. 69−70.
- Odaha M. Mortality in chronic dialysis patients in Japan // Am. J. Kidney Dis. -1990.-Vol. 15.-P. 410−413.
- Packer M., O’Connor C.M., Ghali J.K. Effect of amlodipine on morbidity and mortality in severe chronic heart failure for the prospective randomized amlodipine survival evaluation study group // New Engl. J. Med. 1996. — Vol. 335.-P. 1107−1114.
- Palmer B.F., Herrich W.L. The effect of dialysis of left ventricular contractility. Cardiac disfunction in chronic uremia / Eds. PS Parfrey, JD Harnett. -Norwell. 1992. — Ch. 11. — P. 172−185.
- Parfrey P. S., Foley R.N. The clinic epidemiology of cardiac disease in chronic renal failure // J. Amer. Soc. Nephrol. 1997. — Vol. 10. — P. 11−18.
- Parfrey P. S., Foley R.N., Harnett J.D. Outcome and risk factors for left ventricular disorders in chronic uremia // Nephrol. Dial. Transplant. 1996. -Vol. 11.-P. 1277−1278.
- Parfrey P. S., Foley R.N., Harnett J.D., Kent M.G., Murray D.C., Barre P.E. Outcome and risk factors of ischemic heart disease in chronic uremia // Kidney Int. 49.-P. 1428−1434.
- Parfrey P. S., Griffits S.M., Harnett J.D. Outcome of congestive heart failure, dilated cardiomyopathy, hypertrophic hyperkinetic disease, and ischemic heart disease in dialysis patients // Amer. J. Nephrol. 1990. — № 10. — P. 213−221.
- Parfrey P. S., Harnett J.D. Left ventricular hypertrophy in dialysis patients // Seminar Dialysis. 1992. — Vol. 5. — P. 34.
- Parfrey P. S., Harnett J.D., Griffits S.M. The clinical course of left ventricular hypertrophy in dialysis patients // Nephron 1990. — Vol. 55. — P. l 14−120.
- Pitt В., Byington R.T., Furberg C.D. Effect of amlodipine on cardiovascular events and procedures // Circulation. 2000. — Vol. 102. — P. 1503−1510.
- Port F.K. End-stage renal disease // Kidney Intern. 1995. — Vol. 48, Suppl. 50. — P. S-3-S-6.
- Portoles J., Torralbo A., Martin P. Cardiovascular effects of recombinant human erytropoietin in predialysis patients // Am. J. Kidney Dis. 1997. — Vol. 29. — P.541−548.
- Pouleur H. Abnormalities in cardiac relaxation and other forms of diastolic dysfunction // Congestive heart failure. Pathophysiology, diagnosis and comprehensive approach to management. New York, Budapest, 1994. — Ch. 5. -P. 68−82.
- Prevention of coronary heart disease in clinical practice: recomendation of the task force of the European Society of Cardiology. European Atherosclerosis
- Society and European Society of Hypertension // Eur. Heart J. 1994. — Vol. 15. -P.1300−1331.
- Qing D.J., Ding H., Vadgama J. Elevate myocardial cytosolic calcium impairs insulin-like growth factor-1 stimulated protein syntesis in CREJ // Am. Soc. Nephrol. 1999. — Vol. 10. — P. 84−92.
- Radermacher J., Koch K.M. Treatment of renal anemia by erythropoietin substitution-The effects on the cardiovascular system // Clin. Nephrol. — 1995. — Vol. 44.-P. S56-S60.
- Rain A.E.G., Margreiter R., Brunner F.P. Report on management of renal failure in Europe XXII, 1991 // Nephrol. Dial. Transplant. 1992. — Vol. 7 (Suppl 2).-P. 7−35.
- Raine A.E.G., Roger S.D. Effects of erythropoietin on blood pressure // Am. J. Kid. Dis.-1991.-Vol. 18.-P. 76−83.
- Ritz E., Deppisch R, Stier E. Atherogenesis and cardiac death: are they related to dialysis procedure and biocompatibility? // Nephrol. Dial. Transplant. -1994. Vol. 9, Suppl. 2. — P. 165−172.
- Ritz E., Koch M. Morbidity and mortality due to hypertension in patients with renal failure // Am. J. Kidney Dis. 1993. — Vol. 21, Suppl. 2. — P. 113−118.
- Ritz E., Stefanski A., Rambausek M. The role of the parathyroid glands in the uremic syndrome // Am. J. Kidney Dis. 1995. — Vol. 26. — P. 808−813.
- Rossi M.A., Carillo S.V. Cardiac hypertrophy due to pressure and volume biological phenomena? //Int. J. Cardiol. 1991. — Vol. 31. — P. 133−149.
- Rostand S.G., Rutsky E.A. // Cardiac dysfunction in chronic uremia / Ed. P. S. Parfrey, J.D. Harnett, overload: distinctly different Boston. 1992. — Ch. 4. — P. 54−66.
- Rostand S.G., Sanders C., Kirk K.A., Rutsky E.A., Fraser R.G. Myocardial calcification and cardiac dysfunction in chronic renal failure // Am. J. Med. -1988.-Vol. 85.-P. 651−657.
- Rostand S.G., Sanders P.C., Rutsky E.A. Cardiac calcification in uremia //. Contrib. Nephrol. 1993. — Vol. 106. — P. 26−29.
- Sadler D.B., Brown J., Nurse H., Roberts J. Impact of hemodialysis on left and right ventricular Doppler diastolic filling indices // Am. J. Med. Sci. — 1992. -Vol. 304.-№ 2.-P. 83−90.
- Sanders C., Frank M.S., Rostand S.G. Metastatic calcification of the heart and lungs in end-stage renal disease: detection and quantification by dual-energy digital chest radiography // Am. J. Rentgenol. 1987. — Vol. 149. — P. 881−887.
- Shinichi A., Mamoru Y. Electrocardiographic abnormalities in patients reseiving hemodialysis //Am. Heart J.- 1996.- Vol.131. № 6. — P. 1137−1144.
- Sica D.A., Douglas J.G. The African American Study of Kidney Disease and Hypertension (AASK): new findings // J. Clin. Hypertens. 2001. — Vol. 3. — P. 244−251.
- Silberger J.S., Barre P.E., Prichard S.S. Impact of left ventricular hypertrophy on survival in end-stage renal disease // Kidney Int. 1989. — Vol. 36. — P. 286 290.
- Stack A.G., Bloembergen W.E. Prevalence and Clinical Correlates of Coronary Artery Disease among New Dialysis Patients in the United States: A Cross-Sectional Study//J. Am. Soc. Nephrol.-2001.-Vol.12.-P. 1516−1523.
- Staessen J.A., Bieniaszewsky L., O’Brien E., Gosse P., Hayashi H., Imai Y. Nocturnal blood pressure fall on ambulatory monitoring in a large international database // J. Hypertension 1997. — Vol. 29. — P. 30−39.
- Stolear J.C., Georges B. The predictive value of cardiac troponin T measurements in subjects on regular heamodialysis // Nephrol. Dial. Transplant. 1999.-Vol. 14.-P. 1961−1967.
- Stone E., Cohn d., Deal C., Pollock C. Calcific atrial mass in end-stage renal failure // Nephrol. Dial. Transplant 1997. — Vol. 12. — P. 807−810.
- Straumann E., Bartel 0., Meyer B. Symmetric and asymmetric left ventricular hypertrophy in patients with end-stage renal failure on long-term hemodialysis // Clin. Cardiol. 1998. — Vol. 21. — № 9. — P. 672−678.
- Suzuki H., Nakamoto H., Nemoto H. Control of blood pressure and prevention of end-organ damage in patients with accelerated hypertension by combination with arotinolol and extended release nifedipine // Hypertens-res. 2000. — Vol. 23.-№ 2.-P. 159−166.
- Symons G., Fortune F., Greenbaum R.A., Dandona P. Cardiac hypertrophy, hypertrophic cardiomyopathy, and hyperparathyroidism an association // Br. Heart J. — 1985. — Vol. 54. — P. 539−542.
- Thuraisingham R.C., Tucker В., Lipkin G.W. Left ventricular hypertrophy in early renal failure // Nephrol. Dial. Transplant. 1994. — Vol. 7. — P. 859−860.
- Timio M., Lippi G., Venanzi C. Cardionephrology / Ed. M. Timio, V. Wizemann, S. Venanzi. Assisi. — 1995. — P. 331−336.
- United States Renal Data System: 1999 Annual Data Report // Am. J. Kidney Dis. 1999. — Vol. 34, Suppl. 1. — P. 152.
- Vallance P., Leone A., Calver A. Accumulation of an endohenous inhibitors of nitric oxide synthesis in chronic renal failure // Lancet. 1992. — Vol. 339. — P. 572−575.
- Verdecchia P., Porcellati C., Zampi I. Asymmetric left ventricular remodeling due to isolated septal thickening in patients with systemic hypertension and normal left ventricular mass // Am. J. Cardiol. 1994. — Vol. 73. — P. 247−252.
- Verdecchia P, Schillaci G, Guerrieri M. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension // Circulation. — 1990. -Vol. 81.-P. 528−536.
- Vincenti F., Amend W.J., Abele J., Feduska N.J., Salvatierra O.J. The role of hypertension in hemodialysis-associated atherosclerosis // Am. J. Med. 1980. -Vol. 68.-P. 363−69.
- Wade M.R., Chen Y.J., Soliman M. Myocardial texture and cardiac calcification in uremia // Miner. Electrolyte Metab. 1993. — Vol. 19. — P. 2124.
- Washio M., Okuda S., Mizoul T. Risk factors for left ventricular hypertrophy in chronic hemodialysis patients // Clin. Nephrol. 1997. — Vol. 47. — № 6. — P. 362−366.
- Wizemann V., Kaufinann J., Kramer W. Effect of erythropoietin on ischemia tolerance in anemic hemodialysis patients with confirmed coronary artery disease // Nephron. 1992. — Vol. 62. — P. 161−165.
- Wizemann V., Timio M., Alpert M.A., Kramer W. Options in dialysis therapy: significant of cardiovascular findings // Kidney Int. 1993. — Vol. 43. — № 40. -P. 85−91.
- World Health Statistics Annual 1998.
- Wu S.G., Lin S.L., Wu C.M. Optimal control of blood pressure can reverse left ventricular hypertrophy in uremic hypertensive hemodialysis patients // Kao-Hsiung-I-Hsueh-Ko-Hsueh-Tsa-Chih. 1999. — Vol. 15. — № 2. — P. 62−68.
- Xie G.Y., Berk M.R., Smith M.D., DeMaria A.N. Relation of Doppler transmitral flow patterns to functional status in congestive heart failure // Amer. Heart J. 1996.-Vol. 131. -№ 4.-P. 766−771.
- Yanagi S., Teragaki M., Tahara A. Extensive specifically localized myocardial calcium deposition in a hemodialysis patient // Jpn. Circ. J. 1992. — Vol. 56. -P. 27−31.
- Zager P.G., Nikolic J., Brown R.H. «U» curve association of blood pressure and mortality in hemodialysis patients // Kidney Int. 1998. — Vol. 54. — P. 561−569.
- Zhang WR- Tao LJ- Chen BM Relationship between serum asymmetric dimethylarginine and blood pressure in patients with Hunan // Yi Ke Da Xue Xue Bao. 2002. — Vol. 27. — № 2. — P. 133−134.